CompletedPhase 1

ENX-104 MAD Study for Participants With Major Depressive Disorder With Anhedonia (aMDD)

United Kingdom48 participantsStarted 2025-02-17

Plain-language summary

The study is designed to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of ENX-104 in participants with major depressive disorder with anhedonia (aMDD).

Who can participate

Age range18 Years – 65 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Of non-childbearing potential, defined as either permanently sterilized or postmenopausal and with a negative pregnancy test.
✓. Of childbearing potential and willing to use both a highly effective method of contraception and a condom with any partner or remain abstinent, and with a negative pregnancy test
✓. Not currently breastfeeding or lactating, and not intending to initiate breastfeeding during the course of study conduct

What they're measuring

Number of Participants with Treatment Emergent Adverse Events (TEAE)

Timeframe: From Day 1 up to Day 21

Trial details

NCT IDNCT07253324

SponsorEngrail Therapeutics INC

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2025-11-26

View on ClinicalTrials.gov More Major Depressive Disorder trials